Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Investor Presentation (December 2024)
24 slides from Sanara Medtech's investor presentation, December 2024
Slide 1: Sanara MedTech Overview
Sanara MedTech Overview December 2024
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Sanara MedTech at a Glance
Sanara MedTech at a Glance Ticker (Nasdaq) SMTI A medical technology company focused on Market Cap $317.7M(1) developing and commercializing ~20,240(2) Avg. Daily Volume (TTM) transformative technologies to improve • Sanara Surgical Business Segments • Tissue Health Plus clinical outcomes and reduce
Slide 4: The Sanara MedTech Story
The Sanara MedTech Story Continuous Innovation and Expansion Value Proposition: 2024 Sanara MedTech empowers surgeons to deliver improved patient • Tufts peptide license agreement outcomes by offering high value niche products. • $55 million debt facility to drive future growth 2022 • Signed with ma
Slide 5: Board of Directors
Board of Directors Strategic Leadership from Experienced Professionals Ron Nixon Ann Beal Salamone, M.S. Director Bob DeSutter CEO & Executive Chairman Director • Experience: Rochal Industries, EDC, • Experience: Founder, The Catalyst • Experience: Piper Sandler National Academy of Engineering, Grou
Slide 6: Sanara Surgical Segment
Sanara Surgical Segment 6
Slide 7: Sanara Surgical Segment: Demonstrated Track Record of Strong, Sustained Revenue Growth
Sanara Surgical Segment: Demonstrated Track Record of Strong, Sustained Revenue Growth Net revenues in millions $ $70.0 $65.0 $60.0 $50.0 $45.8 $40.0 $30.0 $24.1 $20.0 $15.6 $11.8 $10.0 $0.0 2019 2020 2021 2022 2023 * For the periods presented, represents net revenues on a consolidated basis, as the
Slide 8: Sanara Surgical Segment: Portfolio Built to Complement Surgical Outcomes
Sanara Surgical Segment: Portfolio Built to Complement Surgical Outcomes & Reduce Post-Op Cost Empowering surgeons to deliver improved patient outcomes by offering high value niche products. Sales Overview Key Differentiators Driving Future Growth • Products contracted or approved to be sold in >4,0
Slide 9: Superior Product Offering with Significant Opportunity Runway
Sanara Surgical Segment: Superior Product Offering with Significant Opportunity Runway Platform Products CellerateRX® Surgical Activated Collagen BIASURGE® Advanced Surgical Solution Surgical Cleanser Soft Tissue Surgical Powder Gel A Type I bovine Hydrolyzed collagen No rinse irrigation solution th
Slide 10: CellerateRX Surgical: Proven, Safe, and Effective
CellerateRX® Surgical Proven, Safe, and Effective Overview • CellerateRX® Surgical Powder is a medical hydrolysate of Type I bovine collagen and contains no additives • Indicated for the management of acute and chronic wounds including: • Surgical wounds • Traumatic wounds • Partial and full-thickne
Slide 11: CellerateRX Surgical Studies
CellerateRX® Surgical Studies Supports Wound Management To Reduce Surgical Site Infection Hydrolyzed Collagen Significantly Reduces Surgical Site Infections (Nowrouzi and Awad 2023)(1) Objective: Evaluate the effect of using type 1 hydrolyzed collagen in reducing incidence of surgical site infection
Slide 12: Sanara Surgical Segment: Growth Opportunities
Sanara Surgical Segment: Growth Opportunities Existing Acute Surgical Wound Growth • The majority of CellerateRX® Surgical cases have been in the Ortho and Spine specialties. • Team is working to further penetrate the >1,200 hospitals where our products are currently sold… • …while also expanding in
Slide 13: Tissue Health Plus Segment
Tissue Health Plus Segment 13
Slide 14: Tissue Health Plus Segment: Opportunity & Overview
Tissue Health Plus Segment: Opportunity & Overview Significant Opportunity to Reduce Cost of Care in Overview of Tissue Health Plus (“THP”): Non-Surgical Wound Care: • A first of its kind value-based wound care program targeting payors • Represents ~$69B(1) of annual expenditure in U.S. Q2 Objective
Slide 15: Planned Tissue Health Plus Model
Planned Tissue Health Plus (“THP”) Model Connected Payor Q2 Objectives Engaged Performant Patient Network THP Care Hub: Hands On Orchestrator INTEGRATED CARE MODEL THP SCALER PLATFORM 15 Commercial launch expected in mid-2025
Slide 16: Q3 2024 Financial Highlights
Q3 2024 Financial Highlights 16
Slide 17: Q3 2024 Financial Highlights
Q3 2024 Financial Highlights (Unaudited) • Total Company • Sanara Surgical Segment • Net revenue of $21.7M (+35% year-over-year) • Segment net loss of $0.2M in Q3 and $2.9M YTD • Twelfth consecutive record net revenue quarter • Segment EBITDA(1) of $2.6M in Q3 and $5.1M YTD • Highest net revenue qua
Slide 18: Thank You
Thank You Sanara MedTech Evidence Based Healing
Slide 19: Appendix
Appendix ~ MedTech Evidence Based Healing « Sanara
Slide 20: Q3 2024 Financial Summary
Q3 2024 Financial Summary (unaudited) • Revenue • For the three months ended September 30, 2024, Sanara generated net revenue of $21.7 million compared to net revenue of $16.0 million for the three months ended September 30, 2023, a 35% increase from the prior year period. • The higher net revenue f
Slide 21: Q3 2024 Financial Summary (Continued)
Q3 2024 Financial Summary (Continued) • Depreciation, Amortization and Interest Expense • Depreciation and amortization expenses for the three months ended September 30, 2024 were $1.1 million compared to $1.0 million for the same period in 2023. The higher depreciation and amortization expenses in
Slide 22: Q3 2024 Segment Reporting
Q3 2024 Segment Reporting • Segment Reporting Overview • Break out of Tissue Health Plus and Sanara Surgical demonstrates our strategic rationale of the acute/post acute comprehensive strategy investments. Three Months Ended September 30, 2024 Three Months Ended September 30, 2023 Surgical THP Total
Slide 23: Non-GAAP Financial Measures
Non-GAAP Financial Measures Use of Non-GAAP Financial Measures To supplement the Company’s financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present certain non-GAAP financial measures in this presentation, including Adjuste
Slide 24: Reconciliation of GAAP to Non-GAAP Financial Measures (Consolidated)
Reconciliation of GAAP to Non-GAAP Financial Measures (Consolidated) Three Months Ended September 30, 2024 2023 Sanara Sanara Surgical THP Total Surgical THP Total Net Income (Loss) $ (180,488) $(2,702,564) $(2,883,052) $ 567,235 $(1,662,184) $(1,094,949) Adjustments: Interest expense 927,577 - 927,
Sanara MedTech — Investor Presentation (December 2024) on 6ix